Nasiriyah Heart Center

Dr. Dennis Doan Champions Future Medical Leaders through Scholarship

Retrieved on: 
Thursday, December 14, 2023
Medicine, American College of Cardiology, Research, Cardiology, Nasiriyah Heart Center, FACC, American College, Interventions, MBA, MD, Medical City, Society, Health, Moyamoya disease, Hospital, Management, Nursing

FORT WORTH, Texas, Dec. 14, 2023 /PRNewswire/ -- Dr. Dennis Doan , an esteemed figure in cardiology, launches the Dr. Dennis Doan Scholarship for Medical Students, a testament to his dedication to nurturing the next generation of medical professionals.

Key Points: 
  • FORT WORTH, Texas, Dec. 14, 2023 /PRNewswire/ -- Dr. Dennis Doan , an esteemed figure in cardiology, launches the Dr. Dennis Doan Scholarship for Medical Students, a testament to his dedication to nurturing the next generation of medical professionals.
  • With a career spanning over two decades, Dr. Dennis Doan , MD, MBA, FACC, RVPI, has consistently exemplified unwavering commitment to healthcare excellence.
  • His vision for healthcare education and his belief in nurturing the upcoming generation of medical talent led to the establishment of the Dr. Dennis Doan Scholarship for Medical Students.
  • For further information about the Dr. Dennis Doan Scholarship for Medical Students and to access the application, please visit https://drdennisdoanscholarship.com .

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Retrieved on: 
Tuesday, October 3, 2023
Research, General Health, Radiology, Professional Services, Pharmaceutical, Clinical Trials, Science, Legal, Cardiology, Biotechnology, Finance, Health, Medical Affairs Bureau, University, GOSS, PAH, Rainer, Bio, Nasiriyah Heart Center, University of Giessen, Actelion, Pulmonary hypertension, Gossamer, MD, Patient, Tadalafil, Entrepreneurship, Johnson & Johnson, Orthostatic hypertension, University of Oxford, Pharmaceutical industry, CSF1R

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs.
  • Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine.
  • “We are thrilled to have Rainer join us at such a critical juncture for the seralutinib program.
  • For nine years, Dr. Zimmerman oversaw the clinic for children with PAH/PH at the Heart Center, University of Giessen, Germany.

SpectraWAVE Secures 510(k) Clearance to Add Saline Imaging and Expanded Artificial Intelligence Features to the HyperVue™ Imaging System

Retrieved on: 
Tuesday, September 19, 2023
Technology, Medical Devices, Medical Supplies, FDA, Health Technology, Cardiology, Hardware, Health, Artificial Intelligence, Plaque, Blood vessel, Myocardial infarction, EEL, Fractional flow reserve, Food and Drug Administration, NIRS, CAD, Nasiriyah Heart Center, Intelligence, Multimedia, Angiography, Meta-analysis, Calcium, Congress, Acquisition, Patient, Physician, Risk, Algorithm, Artificial intelligence, St. Francis Hospital, Coronary artery disease, European Society of Cardiology, Arrest, Food, Medical imaging

The intravascular imaging system combines next-generation DeepOCT™ images and near infrared spectroscopy (NIRS) with state-of-the-art ease of use to support physicians optimizing coronary stenting in the cardiac catheterization lab.

Key Points: 
  • The intravascular imaging system combines next-generation DeepOCT™ images and near infrared spectroscopy (NIRS) with state-of-the-art ease of use to support physicians optimizing coronary stenting in the cardiac catheterization lab.
  • Newly cleared product enhancements include contrast-free saline imaging, artificial intelligence algorithms to support the identification of key clinical structures of calcium and external elastic lamina (EEL), and hands-free angiographic co-registration.
  • The latest clearance adds to the existing HyperVue toolkit , which includes artificial intelligence enabled lipid, lumen, stent, and sidebranch detection, as well as the no-flush prep Starlight™ Imaging Catheter designed for efficient setup and image acquisition in complex lesions.
  • Next generation DeepOCT and Near Infrared Spectroscopy intravascular imaging system now includes compatibility with contrast-free saline imaging, advanced artificial intelligence algorithms to identify calcium and external elastic lamina, and hands-free angiographic co-registration.

Us2.ai Partners with Leading Academic Medical Center to Collaborate on AI-Enabled Echocardiography Software

Retrieved on: 
Wednesday, September 13, 2023
Technology, Clinical Trials, Health Technology, Cardiology, Software, Biotechnology, Health, General Health, Artificial Intelligence, PW, Heart, Duke University, CE, Partnership, Society, CW, American Society of Echocardiography, Health policy, Graduate Medical School Admissions Test, Heart failure, Anesthesiology, Echocardiography, Deep learning, Nasiriyah Heart Center, Splenic infarction, Associate, 2D, Duke University School of Medicine, Ischemia, Patient, Valvular heart disease, Algorithm, Artificial intelligence, Diagnosis, Cardiomyopathy, Duke University Health System, FDA, Pulmonary hypertension, Duke–NUS Medical School, Syndrome, Medtech, Medical device, Medical imaging, Doppler effect, Medicine

In clinical practice, echocardiography is now firmly established as a central, affordable front-line tool for diagnosis and management of a range of cardiac conditions.

Key Points: 
  • In clinical practice, echocardiography is now firmly established as a central, affordable front-line tool for diagnosis and management of a range of cardiac conditions.
  • Even at the most well-resourced setting, the process of acquiring, measuring, and analyzing the images is time-consuming and labor-intensive, making the routine echocardiography application unsustainable.
  • Advances in deep learning have made automated analysis of medical images possible,” said Dr. Manesh Patel, Chief of Cardiology and Co-Director of the Heart Center at Duke University Health System.
  • This covers the vast majority of standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography, European Association of Cardiovascular Imaging, and British Society of Echocardiography.

Magenta Medical Completes Enrollment to Early Feasibility Study for World's Smallest Heart Pump

Retrieved on: 
Tuesday, August 22, 2023
Heart, Abdominal aortic aneurysm, Cardiogenic shock, Interventional cardiology, Aneurysm, Cardiac catheterization, Northwell Health, Splenic infarction, Quality of life, Nasiriyah Heart Center, Magenta, Artery, Federal, IVUS, Atherosclerosis, Teaching hospital, PCI, North Shore University Hospital, LAD, Mount Sinai Hospital, Patient, Risk, Elevate, St. Francis Hospital, Hospital, Coronary artery disease, FDA, Mount Sinai Health System, Groin, Safety, Pharmaceutical industry, Medical device, Nursing, Cardiology

KADIMA, Israel, Aug. 22, 2023 /PRNewswire/ -- Magenta Medical, developer of the world's smallest heart pump, announced today the completion of enrollment to its FDA-approved Early Feasibility Study with the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication. All 15 study patients were enrolled and successfully treated at Mount Sinai Hospital, St. Francis Hospital and Heart Center, and North Shore University Hospital. The Elevate™ Early Feasibility Study was approved by the FDA to evaluate the safety and feasibility of the Elevate™ System in providing temporary mechanical circulatory support during HR-PCI procedures, and constitutes the first step in a clinical program intended to secure approval for the device in the US for this indication.

Key Points: 
  • KADIMA, Israel, Aug. 22, 2023 /PRNewswire/ -- Magenta Medical , developer of the world's smallest heart pump, announced today the completion of enrollment to its FDA-approved Early Feasibility Study with the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication.
  • All 15 study patients were enrolled and successfully treated at Mount Sinai Hospital, St. Francis Hospital and Heart Center, and North Shore University Hospital.
  • "Having now used the system in nine complex, high-risk PCI cases, I can truly appreciate its advantages," said Dr. Sharma.
  • The percutaneous Elevate™ heart pump is inserted over a guidewire through commercially available 10 Fr introducer sheaths that require a small puncture in the groin.

First Patients Treated in the US with the World's Smallest Heart Pump

Retrieved on: 
Wednesday, June 7, 2023
Heart, Cardiogenic shock, Interventional cardiology, Instability, Perfusion, Catheter, Splenic infarction, Nasiriyah Heart Center, Magenta, Artery, Federal, Cardiology, PCI, Patient, Risk, St. Francis Hospital, Hospital, Coronary artery disease, FDA, Mount Sinai Health System, Groin, Weaning, Safety, Disease, Pharmaceutical industry, Medical device, Nursing

KADIMA, Israel, June 7, 2023 /PRNewswire/ -- Magenta Medical, developer of the world's smallest heart pump, announced today the initiation of its FDA-approved Early Feasibility Study with the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication. The study began with the treatment of two patients: one in Mount Sinai Health System and one in St. Francis Hospital and Heart Center, both in New York.

Key Points: 
  • The study began with the treatment of two patients: one in Mount Sinai Health System and one in St. Francis Hospital and Heart Center, both in New York.
  • Some of these patients present with more severe disease, making them prone to instability during coronary intervention, and are thus categorized as high-risk.
  • In these patients, it is advantageous to provide mechanical circulatory support during the procedure to preserve systemic blood pressure and maintain perfusion of vital organs, including the heart itself.
  • The percutaneous Elevate™ heart pump is inserted over a guidewire through commercially available 10 Fr introducer sheaths that require a small puncture in the groin.

SpectraWAVE Secures 510(k) Clearance of HyperVue™ Intravascular Imaging System

Retrieved on: 
Wednesday, March 1, 2023
Technology, Surgery, Medical Devices, FDA, Health Technology, Audio, Video, Cardiology, Hardware, Health, Blood vessel, Coronary artery disease, Doctor of Philosophy, Principal, CAD, Workflow, Nasiriyah Heart Center, NIRS, PCI, Interventional cardiology, Acquisition, Risk, Plaque, Food and Drug Administration, St. Francis Hospital, Patient, Calcium, Percutaneous coronary intervention, Food, Ministry of Research, Innovation and Science, Physician, Medical imaging

SpectraWAVE, Inc ., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced Food and Drug Administration (FDA) 510(k) clearance of their flagship intravascular imaging system, HyperVue™.

Key Points: 
  • SpectraWAVE, Inc ., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced Food and Drug Administration (FDA) 510(k) clearance of their flagship intravascular imaging system, HyperVue™.
  • In addition, the system has now been used by multiple physicians as part of a first-in-human study.
  • “This is a landmark day for SpectraWAVE, but more importantly, a critical step towards improving outcomes for patients with coronary artery disease,” said Eman Namati, Ph.D., Chief Executive Officer of SpectraWAVE.
  • The Starlight™ Imaging Catheter delivers rapid pullbacks of both imaging modalities in a single, low-profile, no-flush form factor.

Fourth Generation CathWorks FFRangio® System Receives Regulatory Approval in Japan

Retrieved on: 
Thursday, October 6, 2022
Physician, LinkedIn, Disease, Cardiovascular disease, Diagnosis, List of health departments and ministries, CAD, MHLW, Patient, Intelligence, Twitter, Medtronic, Partnership, Veni, vidi, vici, Automation, Nasiriyah Heart Center, Ministry of Health, Labour and Welfare, Department, CEO, Medicines and Healthcare products Regulatory Agency, Coronary artery disease, Ministry, PMDA, Pharmaceutical industry, Medical device, Health

KFAR-SABA, Israel and IRVINE, Calif., Oct. 6, 2022 /PRNewswire/ -- CathWorks announced today the approval of the fourth generation CathWorks FFRangio System by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

Key Points: 
  • KFAR-SABA, Israel and IRVINE, Calif., Oct. 6, 2022 /PRNewswire/ -- CathWorks announced today the approval of the fourth generation CathWorks FFRangio System by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
  • The CathWorks FFRangio System has been the first non-invasive device of its kind to receive Japan PMDA and Ministry of Health, Labour and Welfare (MHLW) approval for diagnosis of functional ischemia for patients with ischemic CAD.
  • The fourth-generation application includes significant automation and enhancements, while offering the same exceptional 93% diagnostic accuracy when compared to invasive wire-derived FFR.1
    "The PMDA approval of the fourth generation CathWorks FFRangio System is another significant milestone for CathWorks, physicians and patients," said Ramin Mousavi, President and CEO of CathWorks.
  • The CathWorks FFRangio System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated.

Texas Children's Hospital Patient Thriving Today Despite Sudden Cardiac Arrest

Retrieved on: 
Friday, June 3, 2022
Sudden death, Arrest, Life, AED (non-profit), Urgent care center, Prognosis, Pediatrics, Texas Children's Hospital, Baylor University, Conference, Research, Awareness, HMO, Electrophysiology, CEO, News, SCA, SADS, Annals of Pediatric Cardiology, Education, Immaculate Conception Cathedral School, Baylor College of Medicine, Long QT syndrome, Multimedia, University, Physician, Jan, Memorial Hermann–Texas Medical Center, Health, Immaculate Conception, First International Conference on the World-Wide Web, AED, Parent, Twitter, Arrhythmia, ICD, CPR, Hospital, Nasiriyah Heart Center, Texas Medical Center, National, Cardiac arrest, Long, Entertainment, Residential care, Woman

HOUSTON, June 3, 2022 /PRNewswire/ -- Texas Children's Hospital patient Garrett Richardson, 21, is alive today because his quick-thinking teacher was prepared and trained to act within minutes — a blessing his parents, Lake Charles, La. residents Monique and Craig Richardson, remember with gratitude nine years after their son's heart stopped.

Key Points: 
  • He traveled by ambulance to a local hospital, where he was stabilized before being transferred to Texas Children's in the Texas Medical Center.
  • "Genetic cardiac arrhythmias like Long QT Syndrome are among the primary causes of sudden cardiac arrest in young people but they're treatable conditions," said Alice Lara, President and CEO of the SADS Foundation.
  • "Over 7,000 children and young adults are affected by SCA each year, but with increased access to AEDs and CPR training, sudden cardiac arrest doesn't have to be fatal."
  • The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Tower for pediatric research; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children's Hospital West Campus, a community hospital in suburban West Houston; and Texas Children's Hospital The Woodlands, the first hospital devoted to children's care for communities north of Houston.

ARTRYA SIGNS FIRST U.S. HOSPITAL CLINICAL PARTNERSHIP WITH HUNTSVILLE HEART CENTER

Retrieved on: 
Tuesday, May 10, 2022
Australian Securities Exchange, Nasiriyah Heart Center, Deep learning, LLC, Algorithm, Coronary artery disease, AYA, Company, Degenerative disease, Biomarker, Physician, Moyamoya disease, CCTA, Patient, Partnership, CT, Diagnosis, MD, Technology, AI, ASX, Risk, Intelligence, Willow, Medical device, Medical imaging, Pharmaceutical industry

HUNTSVILLE, Ala., May 10, 2022 /PRNewswire/ -- Artrya Ltd, creator of the AI-based cardiac software solution Artrya Salix, today announced its first U.S. clinical partnership with Alabama-based Huntsville Heart Center, Inc, a national leader in coronary computed tomography angiography (CCTA) that treats more than 80,000 cardiac patients per year.

Key Points: 
  • HUNTSVILLE, Ala., May 10, 2022 /PRNewswire/ -- Artrya Ltd, creator of the AI-based cardiac software solution Artrya Salix, today announced its first U.S. clinical partnership with Alabama-based Huntsville Heart Center, Inc, a national leader in coronary computed tomography angiography (CCTA) that treats more than 80,000 cardiac patients per year.
  • As part of the initial agreement, Heart Center Research, LLC, a division of Huntsville Heart Center, will conduct a study to determine the efficacy of Artrya' s technology.
  • In the study, Heart Center researchers will utilize CT scans that were previously obtained for indicated clinical purposes.
  • Artrya USA Co-CEO's, Jory Tremblay and Ted Schwab, said: "This is the Company's first clinical partnership in the U.S., and we are pleased that such a well-regarded heart center has joined in our mission to create better detection of the world's leading killer -- heart disease."